NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
8 trialsNCT00619424 2017-11-17
A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00678977 2017-11-14
A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00866528 2017-11-13
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00549328 2014-11-19
Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT01313663 2014-10-27
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
GlaxoSmithKline
Phase 2 Terminated
NCT00871403 2013-06-20
Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00367679 2012-06-12
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed